**Name of Journal: *World Journal of Clinical Oncology***

**Manuscript NO: 33577**

**Manuscript Type: Minireviews**

**Current state and controversies in fertility preservation in women with breast cancer**

Taylan E *et al*. Fertility preservation in women with breast cancer

**Enes Taylan, Kutluk H Oktay**

**Enes Taylan, Kutluk H Oktay,** Innovation Institute for Fertility Preservation and In Vitro Fertilization, New York, NY 10019, United States

**Enes Taylan, Kutluk H Oktay,** Laboratory of Molecular Reproduction and Fertility Preservation, Department of Obstetrics and Gynecology, New York Medical College, Valhalla, NY 10595, United States

**Author contributions:** Both authors contributed to this paper with conception, literature review and analysis, drafting, revision, editing, and approval of the final version.

**Conflict-of-interest statement:** No potential conflicts of interest.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Correspondence to:** **Kutluk H Oktay MD, PhD,** Laboratory of Molecular Reproduction and Fertility Preservation, Department of Obstetrics and Gynecology, New York Medical College, 40 Sunshine Cottage Rd, Valhalla, NY 10595, United States. [koktay@fertilitypreservation.org](mailto:koktay@fertilitypreservation.org)

**Telephone:**+1-877-4923666

**Received:** February 17, 2017

**Peer-review started:** February 17, 2017

**First decision:** April 14, 2017

**Revised:** May 4, 2017

**Accepted:** May 12, 2017

**Article in press:**

**Published online:**

**Abstract**

On average, over 25000 women are diagnosed with breast cancer under the age of 45 annually in the United States. Because an increasing number of young women delay childbearing to later life for various reasons, a growing population of women experience breast cancer before completing childbearing. In this context, preservation of fertility potential of breast cancer survivors has become an essential concept in modern cancer care. In this review, we will outline the currently available fertility preservation options for women with breast cancer of reproductive age, discuss the controversy behind hormonal suppression for gonadal protection against chemotherapy and highlight the importance of timely referral by cancer care providers.

**Key words:** Fertility preservation; Female breast cancer; Cryopreservation; Oocyte; embryo; Ovarian suppression; Gonadotropin-releasing hormone agonist; Letrozole; Ovarian tissue cryopreservation

© **The Author(s) 2017**. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Field of fertility preservation has experienced remarkable advances within the last 20 years. As a result, young cancer survivors have numerous options to maintain an important aspect of their quality of life, fertility. In this article we review the current state and controversies in fertility preservation. The article should be an important resource for professionals who take care of young women with breast cancer and other malignancies.

Taylan E, Oktay KH. Current state and controversies in fertility preservation in women with breast cancer. *World J Clin Oncol* 2017; In press

**INTRODUCTION**

Breast cancer is the most common malignancy in women and on average more than 25000 women are diagnosed with breast cancer before reaching the age of 45 years, each year in the United States[1]. Early diagnosis by virtue of significant advances in detection, and newly developed treatment strategies have remarkably improved the course of breast malignancies. According to the National Cancer Institute, 5-year-survival rate for the women under age 45 was estimated to be as high as 88%-98.5% in 2011[2].

While survivorship rates have dramatically increased in women with breast cancer, an important issue related to reproductive function has emerged. Most women with breast cancer are likely to undergo systemic adjuvant or neo-adjuvant chemotherapy with gonadotoxic side effects. As a consequence, preserving fertility potential has become an essential concept in the management of young cancer survivors. Fertility preservation has emerged from this concept as a new and dynamic discipline where oncology and reproductive medicine intersect.

In this review, we aimed to highlight the importance of fertility preservation as a part of routine care for breast cancer patients of childbearing age and outline the key fertility preservation options along with still experimental but promising therapeutic procedures.

**COUNSELING FOR FERTILITY PRESERVATION**

Because of the trend for having children in later reproductive ages, the number of women who experience breast cancer before completing childbearing is growing. Coupled with the increased survival rates and the growing healthy survivor population, fertility preservation has become an important component of cancer care and the maintenance of quality of life for survivors[3].

American Society of Clinical Oncology (ASCO) and American Society of Reproductive Medicine (ASRM) guidelines for fertility preservation in cancer patients strongly recommend that oncologist should inform their patients about the potential negative effects of chemotherapy on fertility before the initiation of the planned treatment and promptly refer patients to reproductive specialist to discuss the risk of ovarian damage and currently available fertility preservation options[4,5]. However, less than half of the oncologists in the United States always or often refer their cancer patients with fertility-related questions to fertility preservation specialist[6].

It should be stressed that providing timely and accurate information for women of reproductive age with breast cancer is critical for the preservation of future fertility chances before complete loss of the limited and irreplaceable ovarian reserve due to chemotherapy. We have previously shown that early referral of breast cancer patients, especially before breast surgery results in larger number of oocytes and embryos being cryopreserved and less time to the initiation of chemotherapy[7].

**IMPACT OF CANCER TREATMENT ON OVARIAN RESERVE**

Modern chemotherapeutic agents that are in use for breast cancer treatment can have a spectrum of ovarian toxicity, depending on the class of the agent, age of the patient, and the cumulative dose[8]. We have shown that the most gonadotoxic agents are those that mainly target oocyte genome causing DNA double strand breaks (DBSs)[9]. Under normal circumstances, DNA repair mechanisms are capable of maintaining genomic integrity, however, at the level of severe DNA damage due to genotoxic agents, those repair mechanisms remain insufficient. The severe DNA damage consequently leads to apoptotic death[9]. Ovarian reserve is made up of about 1 million primordial follicle oocytes at birth, and this number is reduced to approximately 500000 at the onset of puberty. These numbers are reduced to about 25000 at age 37 and nearly exhausted at menopause. Because primordial follicles cannot be regenerated, any chemotherapeutic agent that induces DNA breaks in primordial follicle oocyte will result in apoptotic death and cause irreversible reduction in ovarian reserve[9].

Among all gonadotoxic agents, those belong to the alkylating category such as cyclophosphamide, are the most gonadotoxic agents[10]. Because alkylating agents are non cell-cycle specific chemical compounds and hence can target and damage resting primordial follicles that constitute ovarian reserve[9,10].

The risk of chemotherapy-induced ovarian damage has been investigated in numerous clinical studies. Unfortunately, menstruation was used as the surrogate for ovarian function and fertility in the majority of the past studies [11]. However, return of menses is a poor surrogate for reproductive potential, and ovarian reserve might be severely diminished despite the resumption of regular menses[12,13]. In this context, it is reported that after treatment with CMF protocol (Cyclophosphamide/Methotrexate/ 5-Fluorouracil) 20%-70% of women younger than age 40 experienced amenorrhea[14]. Comparing CMF protocol to the AC protocol (Doxorubicin/ Cyclophosphamide), significantly lower rates of amenorrhea (69% *vs* 34%, respectively) have been reported with the AC protocol[15]. This finding is most likely related to a lower cumulative dose of cyclophosphamide reached with AC regimen. When a taxane administered in combination with AC (AC-T), it did not significantly increase the risk of amenorrhea compared with standard AC regimen[16]. Tables 1 and 2 summarize chemotherapeutic agents that are commonly used in breast cancer treatment and their potential impact on ovarian function[15-19].

Patient age at the time of chemotherapy inversely correlates with the likelihood of post-chemotherapy amenorrhea. In women with breast cancer, while the incidence of chemotherapy-induced amenorrhea was reported as 15%-40% under the age of 30, this incidence dramatically increases to 49%-100% for women older than 40 years of age[20]. The reason for this age-related difference is the fact that younger women have a larger ovarian reserve. Our previous studies indicated that on average, gonadotoxic chemotherapy regimens result in the loss of approximately 10 years worth of ovarian reserve[21]. Though both younger and older women would lose follicles, gonadotoxic chemotherapy is more likely to push older women over the threshold for menopause as they have lower reserve to begin with. However, regardless of age, females of all ages, including children, are expected to experience early menopause after exposure to gonadotoxic chemotherapy agents. Therefore fertility preservation and completion of family building as early as possible, is critical regardless of the age at chemotherapy exposure in most instances[22].

**GONADOTROPIN-RELEASING HORMONE ANALOGS AND OVARIAN PROTECTION**

There has been an ongoing controversy regarding the role of ovarian suppression in cancer patients using gonadotropin-releasing hormone (GnRH) analogs in order to protect ovaries from chemotherapy-induced damage[23].

The biggest concern regarding the effectiveness of ovarian suppression is that primordial follicles that constitute the ovarian reserve are quiescent and do not express gonadotropin or GnRH receptors[24,25]. Thus, any change in gonadotropin or GnRH serum levels has no plausible direct or indirect effect on primordial follicles (Figure 1). Furthermore, we have shown that gonadotoxic agents induce primordial follicle death *via* inducing DNA double strand breaks in oocytes in a non-cell cycle dependent fashion, hence there is no mechanism for ovarian suppression by GnRHa to prevent chemotherapy-induced DNA damage[9,26]. It should be recognized that GnRHa induces a hormonal state similar to prepubertal stage, and if ovarian suppression were to be protective, children of prepubertal age would be resistant to gonadotoxic effects of chemotherapy, which is shown to be not to be the case[27].

While some studies in women with breast cancer, which used menstruation as a marker, suggested some benefit in restoration of menstruation post-chemotherapy, these studies were marred by numerous weaknesses[28-30]. These include the utility of self-reported menstrual status, a highly unreliable surrogate for fertility, lack of placebo control (instead of GnRHa) or blinding, and lack of correction for the difference in desire to conceive between study and control groups[31].

Use of amenorrhea as the sign of ovarian failure is also key weakness in trials of GnRHa for ovarian protection. Especially for breast cancer patients, chemotherapy often induces occult ovarian insufficiency that most frequently presents as irregular or even normal appearing periods rather than amenorrhea. When the serum anti-Müllerian Hormone (AMH), which is the most reliable quantitative biomarker for ovarian reserve or appropriate criteria with serum FSH levels for defining ovarian failure was used, none of the studies showed fertility preservation benefit from GnRHa treatment[32-34].

Given the contradictory results and ovarian biological facts, the use of GnRHa for the prevention of ovaries from chemotherapy damage is still controversial and cannot be recommended as an effective method of fertility preservation.

**OVARIAN RESERVE IN WOMEN WITH BRCA MUTATIONS**

Most hereditary breast cancers are associated with germline mutations in *BRCA1* and *BRCA2* genes. BRCA genes are members of the ataxia-telangiectasia-mutated (ATM)-mediated DNA damage signaling pathway and are essential for DNA double-strand break (DSB) repair[35]. In addition to the increased risk for multiple malignancies, several clinical and experimental studies showed an association between BRCA mutations and diminished ovarian reserve[26,36-41]. While performing ovarian stimulation in women with breast cancer by using aromatase inhibitors for fertility preservation, we found significantly lower ovarian response rates in BRCA mutation carries particularly, among those with BRCA1 mutations[36]. In another important study, authors reported that unaffected women with BRCA mutation experience menopause 3-4 years earlier than healthy controls[38]. Recently, our laboratory showed that in BRCA1 mutant mice there is increased age-related accumulation of DNA double strand breaks in primordial follicle oocytes and the ovarian reserve is significantly lower. These BRCA1 mutant mice also showed reduced litter size and poor embryo development. These findings clearly indicate a biological connection between BRCA mutations, DNA repair and reproductive function. In the same study, we also showed that affected women with BRCA1 mutations had lower serum AMH levels compared to controls. Interestingly we did not find these differences in either BRCA2 mutant mice or affected women with BRCA mutations[26]. Confirming our findings in a prospective study, Philips et al. found 25% lower AMH concentrations on average in BRCA1 carriers compared to non-carriers. There was no significant association between the BRCA2 mutation status and the AMH levels[41].

Given the accumulating evidence that the ovarian reserve may be lower in women with BRCA mutations, it is possible that these women are more prone to chemotherapy-induced loss of ovarian reserve and ovarian insufficiency. However this is yet to be shown in prospective clinical trials. Nevertheless, while counseling women with BRCA mutations on fertility preservation, the possibility of higher risk of chemo-induced infertility should not be omitted.

**FERTILITY PRESERVATION OPTIONS FOR BREAST CANCER PATIENTS**

Embryo cryopreservation after *in vitro* fertilization (IVF) is currently considered as an established fertility preservation option, which offers the best chance of livebirth for women with a partner or single women who elect to use donor sperm. Numerous studies have demonstrated up to 60% clinical pregnancy rates and around 34% livebirth rates after transfer of frozen-thawed embryos in infertility patients with mean age of 35.1 ± 4.03, which is comparable to fresh embryo transfer[42,43]. When preimplantation genetic screening utilized, the livebirth rates can increase up to 77% after transfer of euploid frozen-thawed embryos[44]. In women with breast cancer with the mean age of 35.8 ± 4.1, we have shown a livebirth rate of 45%, which appeared to be superior to those undergoing frozen embryo transfer for infertility[45].

Cryopreservation of mature or immature oocytes is another fertility preservation option for women without a partner and those not wishing to use donor sperm due to legal, ethical or religious considerations. Mature oocytes can be effectively cryopreserved using a vitrification method and the success rates of post-thaw fertilization and pregnancy rates have approached those with fresh oocytes in young patients, though success rates with frozen embryos may still be better[46,47]. Oocyte cryopreservation success rates vary depending on age, number of oocytes frozen and the freezing protocol. In a recent individual patient data meta-analysis we calculated these success rates[48]. (An interactive online success rate estimator can be found online at http://fertilitypreservation.org/index.php/probability-calc).

Based on an individual patient meta-analysis encompassing thaw cycles with frozen oocytes, we have calculated the age-based success rates for oocyte cryopreservation. An interactive online egg freezing success rate estimator can be found at this link: http://fertilitypreservation.org/index.php/probability-calc, and can be useful in patient counseling.

Immature oocytes can be obtained from patients without undergoing ovarian stimulation due to dearth of time and also at the time of ovarian tissue harvesting for fertility preservation. After retrieval, immature oocyte may be cryopreserved before or after undergoing *in vitro* maturation (IVM) process[49]. Lee *et al*[50] suggested performing IVM for immature oocytes before cryopreservation rather than post-thaw as they observed significantly higher maturation and survival rates with that approach. Although IVM is still an experimental fertility preservation method and limited to a number of fertility centers, this method has recently resulted in live births[51].

Embryo and oocyte cryopreservation methods are widely used and currently considered as established methods of fertility preservation. However, typically 10-14 d of controlled ovarian stimulation is needed to obtain mature oocytes (Table 3).

When there is insufficient time for ovarian stimulation, the only available strategy other than immature oocyte retrieval and IVM for women with breast cancer is ovarian tissue harvesting and cryopreservation for future transplantation. Since the first report of ovarian transplantation with cryopreserved tissue by our group, there have been more than 80 livebirths with over 30% of livebirth rate after ovarian transplantation[52,53]. Some have raised the concern of reintroducing malignant cells back into the body along with ovarian tissue. However, studies showed no evidence of malignant cells in cryopreserved ovarian tissues from non-metastatic breast cancer patients and those with bone and soft tissue tumors[54-56].

**CONTROLLED OVARIAN STIMULATION PROTOCOLS**

The major issue associated with the conventional ovarian stimulation protocols is elevated circulating estradiol levels due to the development of large number of follicle at once. Therefore, conventional stimulation protocols are considered unsafe in women with estrogen-sensitive breast cancer.

Although oocytes can be retrieved from ovaries without performing ovarian stimulation (natural cycle IVF), this strategy typically does not provide more than one oocyte per cycle and yield an embryo in only 60% of cycles[57]. On the other hand, use of tamoxifen alone for ovulation induction showed better results in mature oocyte and embryo yield compared to natural cycle IVF[58]. Tamoxifen may also be used in combination with low dose gonadotropins for IVF, resulting in increase multiple mature oocytes and embryos[59].

While reducing the circulating estrogen levels, aromatase inhibitors induce the secretion of endogenous FSH by releasing the hypothalamic-pituitary axis from estrogenic negative feedback[60]. We showed that letrozole in combination with gonadotropins can produce comparable outcomes to conventional IVF while providing significantly lower estradiol levels and decreased gonadotropin requirements[45]. We also showed that pregnancy outcomes after ovarian stimulation with letrozole protocol in premenopausal breast cancer patients before adjuvant chemotherapy were similar to a non-cancer population[60]. Moreover, after short and mid-term follow up letrozole-gonadotropin protocol was associated with disease free survival rates[61].

One of the concerns related with ovarian stimulation before adjuvant or neo-adjuvant chemotherapy is the delay in the initiation of breast cancer treatment. However, studies have shown that initiation of chemotherapy can be delayed up to 12 wk after breast surgery without any adverse effect on survival and recurrence rates[62,63].

Another concern is that letrozole protocol is that it is a teratogenic agent if used during pregnancy. However, in the setting of fertility preservation, embryos are never exposed to letrozole as the fertilization takes place in vitro and the resultant embryos are cryopreserved for later use. Additionally, it has been reported that there was no difference in congenital malformation and chromosomal abnormality rates among children born after ovarian stimulation with clomiphene or letrozole for infertility[64].

**PREGNANCY AFTER BREAST CANCER**

Patients in the decision process for fertility preservation treatments frequently question the safety of pregnancy after completion of cancer treatment. Based on the current evidence, pregnancy after breast cancer is not associated with increased risk of adverse outcomes[65]. In general, patients are advised to delay pregnancy at least 2 years after diagnosis, as the risk of recurrence is highest in this time frame. In the case of ER-positive breast cancer, pregnancy is contraindicated during tamoxifen treatment because of teratogenicity. For breast cancer survivors who do not want to delay childbearing for the completion of tamoxifen treatment or for those with other medical contraindications, gestational surrogacy may be a suitable option to utilize their frozen eggs or embryos in the future[10,65].

**CONCLUSION**

Fertility preservation has become a crucial part of survivorship and an important aspect of comprehensive cancer care. Fortunately, there are several well-established treatment options including embryo and oocyte cryopreservation and safer ovarian stimulation protocols. Moreover, there are emerging experimental methods such as ovarian tissue cryopreservation and transplantation and IVM, which are showing promise. To maximize the utility of these available options and avoid significant delays in the initiation of chemotherapy, timely referral to fertility preservation counseling should be an integral part of the care of young women with breast cancer.

**REFERENCES**

1 **SEER Stat Fact Sheets: Female Breast Cancer.** [accessed 2017 Jan 15]. Available from: URL: http: //seer. cancer.gov/statfacts/html/breast.html

2 **Howlader N,** Noone AM, Krapcho M eds, SEER Cancer Statistics Review, 1975–2011. National Cancer Institute: Bethesda, MD

3 **Partridge AH**, Gelber S, Peppercorn J, Sampson E, Knudsen K, Laufer M, Rosenberg R, Przypyszny M, Rein A, Winer EP. Web-based survey of fertility issues in young women with breast cancer. *J Clin Oncol* 2004; **22**: 4174-4183 [PMID: 15483028 DOI: 10.1200/JCO.2004.01.159]

4 **Loren AW**, Mangu PB, Beck LN, Brennan L, Magdalinski AJ, Partridge AH, Quinn G, Wallace WH, Oktay K; [American Society of Clinical Oncology](https://www.ncbi.nlm.nih.gov/pubmed/?term=American%20Society%20of%20Clinical%20Oncology%5BCorporate%20Author%5D). Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. *J Clin Oncol* 2013; **31**: 2500-2510 [PMID: 23715580 DOI: 10.1200/JCO.2013.49.2678]

5 [Ethics Committee of American Society for Reproductive Medicine](https://www.ncbi.nlm.nih.gov/pubmed/?term=Ethics%20Committee%20of%20American%20Society%20for%20Reproductive%20Medicine%5BCorporate%20Author%5D). Fertility preservation and reproduction in patients facing gonadotoxic therapies: a committee opinion. *Fertil Steril* 2013; **100**: 1224-1231 [PMID: 24094423 DOI: 10.1016/j.fertnstert.2013.08.041]

6 **Quinn GP**, Vadaparampil ST, Lee JH, Jacobsen PB, Bepler G, Lancaster J, Keefe DL, Albrecht TL. Physician referral for fertility preservation in oncology patients: a national study of practice behaviors. *J Clin Oncol* 2009; **27**: 5952-5957 [PMID: 19826115 DOI: 10.1200/JCO.2009.23.0250]

7 **Lee S**, Ozkavukcu S, Heytens E, Moy F, Oktay K. Value of early referral to fertility preservation in young women with breast cancer. *J Clin Oncol* 2010; **28**: 4683-4686 [PMID: 20876425 DOI: 10.1200/JCO.2010.30.5748]

8 **Bedoschi G**, Navarro PA, Oktay K. Chemotherapy-induced damage to ovary: mechanisms and clinical impact. *Future Oncol* 2016; **12**: 2333-2344 [PMID: 27402553 DOI: 10.2217/fon-2016-0176]

9 **Soleimani R**, Heytens E, Darzynkiewicz Z, Oktay K. Mechanisms of chemotherapy-induced human ovarian aging: double strand DNA breaks and microvascular compromise. *Aging (Albany NY)* 2011; **3**: 782-793 [PMID: 21869459 DOI: 10.18632/aging.100363]

10 **Rodriguez-Wallberg KA**, Oktay K. Fertility preservation in women with breast cancer. *Clin Obstet Gynecol* 2010; **53**: 753-762 [PMID: 21048442 DOI: 10.1097/GRF.0b013e3181f96e00]

11 **Levine JM**, Kelvin JF, Quinn GP, Gracia CR. Infertility in reproductive-age female cancer survivors. *Cancer* 2015; **121**: 1532-1539 [PMID: 25649243 DOI: 10.1002/cncr.29181]

12 **Partridge AH**, Ruddy KJ, Gelber S, Schapira L, Abusief M, Meyer M, Ginsburg E. Ovarian reserve in women who remain premenopausal after chemotherapy for early stage breast cancer. *Fertil Steril* 2010; **94**: 638-644 [PMID: 19409543 DOI: 10.1016/j.fertnstert.2009.03.045]

13 **Gracia CR**, Sammel MD, Freeman E, Prewitt M, Carlson C, Ray A, Vance A, Ginsberg JP. Impact of cancer therapies on ovarian reserve. *Fertil Steril* 2012; **97**: 134-40.e1 [PMID: 22137491 DOI: 10.1016/j.fertnstert.2011.10.040]

14 **Gadducci A**, Cosio S, Genazzani AR. Ovarian function and childbearing issues in breast cancer survivors. *Gynecol Endocrinol* 2007; **23**: 625-631 [PMID: 17926162 DOI: 10.1080/09513590701582406]

15 **Bines J**, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. *J Clin Oncol* 1996; **14**: 1718-1729 [PMID: 8622093 DOI: 10.1200/JCO.1996.14.5.1718]

16 **Abusief ME**, Missmer SA, Ginsburg ES, Weeks JC, Partridge AH. The effects of paclitaxel, dose density, and trastuzumab on treatment-related amenorrhea in premenopausal women with breast cancer. *Cancer* 2010; **116**: 791-798 [PMID: 20052714 DOI: 10.1002/cncr.24835]

17 **Ruddy KJ**, Guo H, Barry W, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, Rugo HS, Ellis MJ, Shapira I, Wolff AC, Carey LA, Overmoyer BA, Hudis C, Krop IE, Burstein HJ, Winer EP, Partridge AH, Tolaney SM. Chemotherapy-related amenorrhea after adjuvant paclitaxel-trastuzumab (APT trial). *Breast Cancer Res Treat* 2015; **151**: 589-596 [PMID: 25981899 DOI: 10.1007/s10549-015-3426-z]

18 **Sahin C**, Taylan E, Akdemir A, Ozgurel B, Taskıran D, Ergenoglu AM. The impact of salpingectomy and single-dose systemic methotrexate treatments on ovarian reserve in ectopic pregnancy. *Eur J Obstet Gynecol Reprod Biol* 2016; **205**: 150-152 [PMID: 27592417 DOI: 10.1016/j.ejogrb.2016.08.028]

19 **Akar M**, Oktay K. Restoration of ovarian endocrine function by ovarian transplantation. *Trends Endocrinol Metab* 2005; **16**: 374-380 [PMID: 16126406 DOI: 10.1016/j.tem.2005.06.011]

20 **Hortobagyi GN**, Buzdar AU, Marcus CE, Smith TL. Immediate and long-term toxicity of adjuvant chemotherapy regimens containing doxorubicin in trials at M.D. Anderson Hospital and Tumor Institute. *NCI Monogr* 1986; (1): 105-109 [PMID: 3534581]

21 **Oktem O**, Oktay K. Quantitative assessment of the impact of chemotherapy on ovarian follicle reserve and stromal function. *Cancer* 2007; **110**: 2222-2229 [PMID: 17932880 DOI: 10.1002/cncr.23071]

22 **Rodriguez-Wallberg KA**, Oktay K. Fertility preservation and pregnancy in women with and without BRCA mutation-positive breast cancer. *Oncologist* 2012; **17**: 1409-1417 [PMID: 23006497 DOI: 10.1634/theoncologist.2012-0236]

23 **Oktay K**, Rodriguez-Wallberg K, Munster P. Ovarian protection during adjuvant chemotherapy. *N Engl J Med* 2015; **372**: 2268-2269 [PMID: 26039611 DOI: 10.1056/NEJMc1504241#SA2]

24 **Gerber B**, von Minckwitz G, Stehle H, Reimer T, Felberbaum R, Maass N, Fischer D, Sommer HL, Conrad B, Ortmann O, Fehm T, Rezai M, Mehta K, Loibl S; [German Breast Group Investigators](https://www.ncbi.nlm.nih.gov/pubmed/?term=German%20Breast%20Group%20Investigators%5BCorporate%20Author%5D). Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO study. *J Clin Oncol* 2011; **29**: 2334-2341 [PMID: 21537042 DOI: 10.1200/JCO.2010.32.5704]

25 **Oktay K**, Bedoschi G. Appraising the Biological Evidence for and Against the Utility of GnRHa for Preservation of Fertility in Patients With Cancer. *J Clin Oncol* 2016; **34**: 2563-2565 [PMID: 27217452 DOI: 10.1200/JCO.2016.67.1693]

26 **Titus S**, Li F, Stobezki R, Akula K, Unsal E, Jeong K, Dickler M, Robson M, Moy F, Goswami S, Oktay K. Impairment of BRCA1-related DNA double-strand break repair leads to ovarian aging in mice and humans. *Sci Transl Med* 2013; **5**: 172ra21 [PMID: 23408054 DOI: 10.1126/scitranslmed.3004925]

27 **Sklar CA**, Mertens AC, Mitby P, Whitton J, Stovall M, Kasper C, Mulder J, Green D, Nicholson HS, Yasui Y, Robison LL. Premature menopause in survivors of childhood cancer: a report from the childhood cancer survivor study. *J Natl Cancer Inst* 2006; **98**: 890-896 [PMID: 16818852 DOI: 10.1093/jnci/djj243]

28 **Lambertini M**, Boni L, Michelotti A, Gamucci T, Scotto T, Gori S, Giordano M, Garrone O, Levaggi A, Poggio F, Giraudi S, Bighin C, Vecchio C, Sertoli MR, Pronzato P, Del Mastro L; [GIM Study Group](https://www.ncbi.nlm.nih.gov/pubmed/?term=GIM%20Study%20Group%5BCorporate%20Author%5D). Ovarian Suppression With Triptorelin During Adjuvant Breast Cancer Chemotherapy and Long-term Ovarian Function, Pregnancies, and Disease-Free Survival: A Randomized Clinical Trial. *JAMA* 2015; **314**: 2632-2640 [PMID: 26720025 DOI: 10.1001/jama.2015.17291]

29 **Moore HC**, Unger JM, Phillips KA, Boyle F, Hitre E, Porter D, Francis PA, Goldstein LJ, Gomez HL, Vallejos CS, Partridge AH, Dakhil SR, Garcia AA, Gralow J, Lombard JM, Forbes JF, Martino S, Barlow WE, Fabian CJ, Minasian L, Meyskens FL, Gelber RD, Hortobagyi GN, Albain KS; [POEMS/S0230 Investigators](https://www.ncbi.nlm.nih.gov/pubmed/?term=POEMS%2FS0230%20Investigators%5BCorporate%20Author%5D). Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. *N Engl J Med* 2015; **372**: 923-932 [PMID: 25738668 DOI: 10.1056/NEJMoa1413204]

30 **Del Mastro L**, Boni L, Michelotti A, Gamucci T, Olmeo N, Gori S, Giordano M, Garrone O, Pronzato P, Bighin C, Levaggi A, Giraudi S, Cresti N, Magnolfi E, Scotto T, Vecchio C, Venturini M. Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial. *JAMA* 2011; **306**: 269-276 [PMID: 21771987 DOI: 10.1001/jama.2011.991]

31 **Oktay K**, Turan V. Failure of Ovarian Suppression With Gonadotropin-Releasing Hormone Analogs to Preserve Fertility: An Assessment Based on the Quality of Evidence. *JAMA Oncol* 2016; **2**: 74-75 [PMID: 26426406 DOI: 10.1001/jamaoncol.2015.3252]

32 **Elgindy E**, Sibai H, Abdelghani A, Mostafa M. Protecting Ovaries During Chemotherapy Through Gonad Suppression: A Systematic Review and Meta-analysis. *Obstet Gynecol* 2015; **126**: 187-195 [PMID: 26241272 DOI: 10.1097/AOG.0000000000000905]

33 **Demeestere I**, Brice P, Peccatori FA, Kentos A, Gaillard I, Zachee P, Casasnovas RO, Van Den Neste E, Dechene J, De Maertelaer V, Bron D, Englert Y. Gonadotropin-releasing hormone agonist for the prevention of chemotherapy-induced ovarian failure in patients with lymphoma: 1-year follow-up of a prospective randomized trial. *J Clin Oncol* 2013; **31**: 903-909 [PMID: 23129737 DOI: 10.1200/JCO.2012.42.8185]

34 **Demeestere I**, Brice P, Peccatori FA, Kentos A, Dupuis J, Zachee P, Casasnovas O, Van Den Neste E, Dechene J, De Maertelaer V, Bron D, Englert Y. No Evidence for the Benefit of Gonadotropin-Releasing Hormone Agonist in Preserving Ovarian Function and Fertility in Lymphoma Survivors Treated With Chemotherapy: Final Long-Term Report of a Prospective Randomized Trial. *J Clin Oncol* 2016; **34**: 2568-2574 [PMID: 27217453 DOI: 10.1200/JCO.2015.65.8864]

35 **Sung P**, Klein H. Mechanism of homologous recombination: mediators and helicases take on regulatory functions. *Nat Rev Mol Cell Biol* 2006; **7**: 739-750 [PMID: 16926856 DOI: [10. 1038/nrm2008](https://doi.org/10.%201038/nrm2008)]

36 **Antoniou A**, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg A, Pasini B, Radice P, Manoukian S, Eccles DM, Tang N, Olah E, Anton-Culver H, Warner E, Lubinski J, Gronwald J, Gorski B, Tulinius H, Thorlacius S, Eerola H, Nevanlinna H, Syrjäkoski K, Kallioniemi OP, Thompson D, Evans C, Peto J, Lalloo F, Evans DG, Easton DF. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. *Am J Hum Genet* 2003; **72**: 1117-1130 [PMID: 12677558 DOI: 10.1086/375033]

37 **Oktay K**, Kim JY, Barad D, Babayev SN. Association of BRCA1 mutations with occult primary ovarian insufficiency: a possible explanation for the link between infertility and breast/ovarian cancer risks. *J Clin Oncol* 2010; **28**: 240-244 [PMID: 19996028 DOI: 10.1200/JCO.2009.24.2057]

38 **Oktay K**, Turan V, Titus S, Stobezki R, Liu L. BRCA Mutations, DNA Repair Deficiency, and Ovarian Aging. *Biol Reprod* 2015; **93**: 67 [PMID: 26224004 DOI: 10.1095/biolreprod.115.132290]

39 **Lin WT**, Beattie M, Chen LM, Oktay K, Crawford SL, Gold EB, Cedars M, Rosen M. Comparison of age at natural menopause in BRCA1/2 mutation carriers with a non-clinic-based sample of women in northern California. *Cancer* 2013; **119**: 1652-1659 [PMID: 23362014 DOI: 10.1002/cncr.27952]

40 **Wang ET**, Pisarska MD, Bresee C, Chen YD, Lester J, Afshar Y, Alexander C, Karlan BY. BRCA1 germline mutations may be associated with reduced ovarian reserve. *Fertil Steril* 2014; **102**: 1723-1728 [PMID: 25256924 DOI: 10.1016/j.fertnstert.2014.08.014]

41 **Phillips KA**, Collins IM, Milne RL, McLachlan SA, Friedlander M, Hickey M, Stern C, Hopper JL, Fisher R, Kannemeyer G, Picken S, Smith CD, Kelsey TW, Anderson RA; [Kathleen Cuningham Consortium for Research into Familial Breast Cancer (kConFab)](https://www.ncbi.nlm.nih.gov/pubmed/?term=Kathleen%20Cuningham%20Consortium%20for%20Research%20into%20Familial%20Breast%20Cancer%20(kConFab)%5BCorporate%20Author%5D). Anti-Müllerian hormone serum concentrations of women with germline BRCA1 or BRCA2 mutations. *Hum Reprod* 2016; **31**: 1126-1132 [PMID: 27094481 DOI: 10.1093/humrep/dew044]

42 **Marrs RP**, Greene J, Stone BA. Potential factors affecting embryo survival and clinical outcome with cryopreserved pronuclear human embryos. *Am J Obstet Gynecol* 2004; **190**: 1766-171; discussion 1766-171; [PMID: 15284794 DOI: 10.1016/j.ajog.2004.02.049]

43 **Check JH**, Katsoff B, Wilson C, Choe JK, Brasile D. Pregnancy outcome following fresh vs frozen embryo transfer into gestational carriers using a simplified slow freeze protocol. *Clin Exp Obstet Gynecol* 2012; **39**: 23-24 [PMID: 22675949]

44 **Coates A**, Kung A, Mounts E, Hesla J, Bankowski B, Barbieri E, Ata B, Cohen J, Munné S. Optimal euploid embryo transfer strategy, fresh versus frozen, after preimplantation genetic screening with next generation sequencing: a randomized controlled trial. *Fertil Steril* 2017; **107**: 723-730.e3 [PMID: 28139240 DOI: 10.1016/j.fertnstert.2016.12.022]

45 **Oktay K**, Turan V, Bedoschi G, Pacheco FS, Moy F. Fertility Preservation Success Subsequent to Concurrent Aromatase Inhibitor Treatment and Ovarian Stimulation in Women With Breast Cancer. *J Clin Oncol* 2015; **33**: 2424-2429 [PMID: 26101247 DOI: 10.1200/JCO.2014.59.3723]

46 **Cobo A**, Garcia-Velasco JA, Domingo J, Remohí J, Pellicer A. Is vitrification of oocytes useful for fertility preservation for age-related fertility decline and in cancer patients? *Fertil Steril* 2013; **99**: 1485-1495 [PMID: 23541405 DOI: 10.1016/j.fertnstert.2013.02.050]

47 **Druckenmiller S**, Goldman KN, Labella PA, Fino ME, Bazzocchi A, Noyes N. Successful Oocyte Cryopreservation in Reproductive-Aged Cancer Survivors. *Obstet Gynecol* 2016; **127**: 474-480 [PMID: 26855092 DOI: 10.1097/AOG.0000000000001248]

48 **Cil AP**, Bang H, Oktay K. Age-specific probability of live birth with oocyte cryopreservation: an individual patient data meta-analysis. *Fertil Steril* 2013; **100**: 492-9.e3 [PMID: 23706339 DOI: 10.1016/j.fertnstert.2013.04.023]

49 **Park CW**, Lee SH, Yang KM, Lee IH, Lim KT, Lee KH, Kim TJ. Cryopreservation of in vitro matured oocytes after ex vivo oocyte retrieval from gynecologic cancer patients undergoing radical surgery. *Clin Exp Reprod Med* 2016; **43**: 119-125 [PMID: 27358831 DOI: 10.5653/cerm.2016.43.2.119]

50 **Lee JA**, Barritt J, Moschini RM, Slifkin RE, Copperman AB. Optimizing human oocyte cryopreservation for fertility preservation patients: should we mature then freeze or freeze then mature? *Fertil Steril* 2013; **99**: 1356-1362 [PMID: 23266213 DOI: 10.1016/j.fertnstert.2012.11.042]

51 **Chian RC**, Huang JY, Gilbert L, Son WY, Holzer H, Cui SJ, Buckett WM, Tulandi T, Tan SL. Obstetric outcomes following vitrification of in vitro and in vivo matured oocytes. *Fertil Steril* 2009; **91**: 2391-2398 [PMID: 18579139 DOI: 10.1016/j.fertnstert.2008.04.014]

52 **Oktay K**, Karlikaya G. Ovarian function after transplantation of frozen, banked autologous ovarian tissue. *N Engl J Med* 2000; **342**: 1919 [PMID: 10877641 DOI: 10.1056/NEJM200006223422516]

53 **Oktay K**, Bedoschi G, Pacheco F, Turan V, Emirdar V. First pregnancies, live birth, and in vitro fertilization outcomes after transplantation of frozen-banked ovarian tissue with a human extracellular matrix scaffold using robot-assisted minimally invasive surgery. *Am J Obstet Gynecol* 2016; **214**: 94.e1-94.e9 [PMID: 26601616 DOI: 10.1016/j.ajog.2015.10.001]

54 **Sánchez-Serrano M**, Novella-Maestre E, Roselló-Sastre E, Camarasa N, Teruel J, Pellicer A. Malignant cells are not found in ovarian cortex from breast cancer patients undergoing ovarian cortex cryopreservation. *Hum Reprod* 2009; **24**: 2238-2243 [PMID: 19491203 DOI: 10.1093/humrep/dep196]

55 **Azem F**, Hasson J, Ben-Yosef D, Kossoy N, Cohen T, Almog B, Amit A, Lessing JB, Lifschitz-Mercer B. Histologic evaluation of fresh human ovarian tissue before cryopreservation. *Int J Gynecol Pathol* 2010; **29**: 19-23 [PMID: 19952943 DOI: 10.1097/PGP.0b013e3181ad1c52]

56 **Dolmans MM**, Iwahara Y, Donnez J, Soares M, Vaerman JL, Amorim CA, Poirel H. Evaluation of minimal disseminated disease in cryopreserved ovarian tissue from bone and soft tissue sarcoma patients. *Hum Reprod* 2016; **31**: 2292-2302 [PMID: 27591237 DOI: 10.1093/humrep/dew193]

57 **Oktay K**, Buyuk E, Davis O, Yermakova I, Veeck L, Rosenwaks Z. Fertility preservation in breast cancer patients: IVF and embryo cryopreservation after ovarian stimulation with tamoxifen. *Hum Reprod* 2003; **18**: 90-95 [PMID: 12525446]

58 **Oktay K**, Buyuk E, Libertella N, Akar M, Rosenwaks Z. Fertility preservation in breast cancer patients: a prospective controlled comparison of ovarian stimulation with tamoxifen and letrozole for embryo cryopreservation. *J Clin Oncol* 2005; **23**: 4347-4353 [PMID: 15824416 DOI: 10.1200/JCO.2005.05.037]

59 **Oktay K**, Hourvitz A, Sahin G, Oktem O, Safro B, Cil A, Bang H. Letrozole reduces estrogen and gonadotropin exposure in women with breast cancer undergoing ovarian stimulation before chemotherapy. *J Clin Endocrinol Metab* 2006; **91**: 3885-3890 [PMID: 16882752 DOI: 10.1210/jc.2006-0962]

60 **Azim AA**, Costantini-Ferrando M, Oktay K. Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: a prospective controlled study. *J Clin Oncol* 2008; **26**: 2630-2635 [PMID: 18509175 DOI: 10.1200/JCO.2007.14.8700]

61 **Turan V**, Bedoschi G, Moy F, Oktay K. Safety and feasibility of performing two consecutive ovarian stimulation cycles with the use of letrozole-gonadotropin protocol for fertility preservation in breast cancer patients. *Fertil Steril* 2013; **100**: 1681-5.e1 [PMID: 24055050 DOI: 10.1016/j.fertnstert.2013.08.030]

62 **Cold S**, Düring M, Ewertz M, Knoop A, Møller S. Does timing of adjuvant chemotherapy influence the prognosis after early breast cancer? Results of the Danish Breast Cancer Cooperative Group (DBCG). *Br J Cancer* 2005; **93**: 627-632 [PMID: 16136052 DOI: 10.1038/sj.bjc.6602734]

63 **Lohrisch C**, Paltiel C, Gelmon K, Speers C, Taylor S, Barnett J, Olivotto IA. Impact on survival of time from definitive surgery to initiation of adjuvant chemotherapy for early-stage breast cancer. *J Clin Oncol* 2006; **24**: 4888-4894 [PMID: 17015884 DOI: 10.1200/JCO.2005.01.6089]

64 **Tulandi T**, Martin J, Al-Fadhli R, Kabli N, Forman R, Hitkari J, Librach C, Greenblatt E, Casper RF. Congenital malformations among 911 newborns conceived after infertility treatment with letrozole or clomiphene citrate. *Fertil Steril* 2006; **85**: 1761-1765 [PMID: 16650422 DOI: 10.1016/j.fertnstert.2006.03.014]

65 **Azim HA**, Kroman N, Paesmans M, Gelber S, Rotmensz N, Ameye L, De Mattos-Arruda L, Pistilli B, Pinto A, Jensen MB, Cordoba O, de Azambuja E, Goldhirsch A, Piccart MJ, Peccatori FA. Prognostic impact of pregnancy after breast cancer according to estrogen receptor status: a multicenter retrospective study. *J Clin Oncol* 2013; **31**: 73-79 [PMID: 23169515 DOI: 10.1200/JCO.2012.44.2285]

**P- Reviewer:** Khajehei M, Wang L, Voutsadakis IA

**S- Editor:** Song XX **L- Editor:** **E- Editor:**

**Specialty type:** Oncology

**Country of origin:** United States

**Peer-review report classification**


Grade A (Excellent): A

Grade B (Very good): B, B

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0



**Figure 1** **Impact of gonadotoxic chemotherapy and gonadotropin-releasing hormone analog (GnRHa) on ovarian reserve and function.** Gonadotoxic chemotherapy reduces ovarian reserve, which is made up of resting and hormone-insensitive primordial follicles, by induction of DNA damage and apoptotic death. GnRHa reduces pituitary GnRH production and, as a result, blocks the release of FSH and LH from the pituitary, which in turn results in the cessation of late-stage follicle development. Because primordial follicles do not have FSH, LH, or GnRH receptors, GnRHa cannot have a direct influence on ovarian reserve. AMH: Anti-Müllerian hormone; FSH: Follicle- stimulating hormone; FSHr: FSH receptor; LH: Luteinizing hormone; LHr: LH receptor; GnRH: Gonadotropin-releasing hormone; GnRHr: GnRH receptor*.* (Oktay *et al*. *J Clin Oncol* 2016; 34: 2563-5, used with permission.)

**Table 1** **The risk of infertility and mechanism of damage associated with chemotherapeutic agents that are commonly used in breast cancer treatment**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Chemotherapeutic agent** | **Class** | **Mechanism of action** | **Cell cycle effect** | **Risk of infertility** |
| *Cyclophosphamide* | Alkylating agent | DNA cross-link formation and double strand breaks that result in inhibition of DNA function and synthesis leading to cellular apoptosis | Cell cycle non-specific | High risk |
| *Doxorubicin* | Anthracyclines | Inhibition of DNA synthesis and function due to inactivation of DNA topoisomerase II, free oxygen radical formation and induction of DNA double-strand breaks | Cell cycle non-specific | Medium risk |
| *Epirubicin* |
| *Carboplatin* | Platinum analog | Inhibition of DNA synthesis and function *via* intra- and interstrand DNA cross-link formation by covalent binding to genome | Cell cycle non-specific | Medium risk |
| *Paclitaxel* | Taxanes | Inhibition of mitotic division by binding to microtubules with enhancement of tubulin polymerization | M phase | Low risk |
| *Docetaxel* |
| *Methotrexate* | Antimetabolites | Inhibition *de novo* purine nucleotide synthesis by inactivation of dihydrofolate reductase | S phase | Low risk |
| *5-Fluorouracil* | Inhibition of DNA synthesis and function *via* inactivation of Thymidylate synthase and alteration in RNA processing | S phase | Low risk |
| *Trastuzumab* | Monoclonal antibodies | Blockage of Human epidermal growth factor receptor 2 subdomain IV, antibody dependent cellular toxicity | NA | Low or no risk |
| *Pertuzumab* | Blockage of Human epidermal growth factor receptor 2 subdomain II, antibody dependent cellular toxicity |

**Table 2** **Common adjuvant chemotherapy regimens for breast cancer and their impact of fertility**

|  |  |  |
| --- | --- | --- |
| **Chemotherapy regimen** | **Risk of amenorrhea or infertility** | |
| **Age ≤ 35** | **Age >35** |
| *CMF* | 4%-40% | 80%-100% |
| *CEF* | 47% | 80%-100% |
| *CAF* | No data | 30% |
| *AC* | 13.9% | 68.2% |
| *AC-T* | 9%-13% | 65%-67% |
| *AC-TH* | 0-14% | 56%-67% |

A: Doxorubicin; C: Cyclophosphamide; E: Epirubicin; F: 5-Fluorouracil; H: Trastuzumab; M: Methotrexate; T: Paclitaxel.

**Table 3** **Fertility Preservation options for reproductive age women with breast cancer**

|  |  |  |  |
| --- | --- | --- | --- |
| **Fertility Preservation Option** | **Current Status** | **Advantages** | **Disadvantages** |
| *Embryo Cryopreservation* | Established | Highest cumulative pregnancy rates | Requires about two weeks delay in the initiation of cancer treatment |
| Requires hormonal stimulation for oocyte retrieval |
| Requires *in vitro* fertilization with male partner or donor sperm |
| *Oocyte Cryopreservation* | Established | No need for male partner or sperm donor | Requires about two weeks delay in the initiation of cancer treatment |
| Requires hormonal stimulation for oocyte retrieval |
| *Ovarian Tissue Cryopreservation and Transplantation* | Currently experimental, may change as success rates are rising | No need for hormonal stimulation | Requires outpatient laparoscopic surgery for ovarian tissue harvesting and subsequent transplantation |
|  |
| No need to significantly delay in the initiation of chemotherapy |
|  |
| No need for male partner or sperm donor |